Tauroursodeoxycholic acid is less damaging than taurochenodeoxycholic acid to the gastric and esophageal mucosa.
Bile acids are capable of disrupting the gastric and esophageal mucosal barriers and are known to differ in their ability to injure these mucosae. Two bile acids, chenodeoxycholic and its 7-B epimer, ursodeoxycholic, that are being used to dissolve gallbladder stones were evaluated for their damaging effects on experimental preparations of the esophageal (rabbit) and gastric (dog) mucosa. Damage was assessed by measuring indices of mucosal barrier function, including net acid flux, potential difference, and tissue resistance, before and after exposure to the taurine conjugates of these bile acids. In both the esophageal and gastric mucosa, tauroursodeoxycholic acid caused significantly less disruption of barrier function than taurochenodeoxycholic acid. These results demonstrate that minor differences in conjugated bile acid structure can cause major changes in the effects of bile acids on the upper gastrointestinal mucosa and that ursodeoxycholic acid may be the preferred bile acid for oral ingestion to dissolve gallbladder stones.
D000818:Animals; D001647:Bile Acids and Salts / Q000627:therapeutic use; D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives*; D002769:Cholelithiasis / Q000188:drug therapy; D004285:Dogs; D004947:Esophagus / Q000187:drug effects*; D005753:Gastric Mucosa / Q000187:drug effects*; D009092:Mucous Membrane / Q000187:drug effects; D011817:Rabbits; D013655:Taurochenodeoxycholic Acid / Q000494:pharmacology*
D001647:Bile Acids and Salts; D002635:Chenodeoxycholic Acid; D013655:Taurochenodeoxycholic Acid; C031655:ursodoxicoltaurine